Form 4 - Statement of changes in beneficial ownership of securities
SEC Accession No. 0000907654-26-000100
Filing Date
2026-09-21
Accepted
2026-09-21 16:57:09
Documents
1
Period of Report
2026-09-21

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 12354
  Complete submission text file 0000907654-26-000100.txt   14197
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Issuer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025
Business Address 650-438-8958
Quinlan Paul T (Reporting) CIK: 0001333277 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-22873 | Film No.: 261394520